9. Humulin

Humulin's sales growth measured a substantial 13% in the U.S.

Company: Eli Lilly
2016 U.S. sales: $862 million
Drug class: Human insulin

Eli Lilly’s Humulin has been around for a long, long time, but it’s still pumping out sales growth. In 2016, that sales growth measured a substantial 13% in the U.S.

The reasons? Demand for the Indianapolis drugmaker’s product increased, it said, and that was the primary driver. But Lilly also benefitted from higher net prices, thanks to a change in the estimate of a government rebate in the first quarter of last year.

For a long time, Lilly kept the growth coming with list price increases on its elderly and long-off-patent med. Between 2007 and 2013, Humulin’s price leapt by 354%, offsetting payer pressure and the termination of an agreement with Walmart.

After taking a 17.5% price hike on Humulin in 2015, however, Lilly cut its increase by more than half to 7.5% in 2016, according to Wells Fargo analyst David Maris. And as of late January of this year, the company had yet to take one at all.

9. Humulin

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.